Answers are grounded in this paper and cite their sources.
In vitro fertilization treatments are still inefficient with only a 60% probability for achieving pregnancy in the first embryo transfer attempt when embryos are euploid. Then, optimizing endometrial diagnosis is one of the main strategies for avoiding the loss of embryos during this inefficient process. In the last years, a new kind of non-timing endometrial failure has been proposed as an idiopathic cause of infertility strongly associated with poor reproductive outcomes. However, effective therapeutic options for treating the endometrium remain lacking, underscoring the need for new personalized treatments that reduce the number of attempts needed for achieving live birth. This multicentre prospective study included 192 endometrial biopsies in mid-secretory phase from patients undergoing In vitro fertilization. Patients were classified as good/poor prognosis endotypes, and next subdivided in subendotypes, according to reproductive success and transcriptomic profiles using machine learning. Therapeutic drugs capable of reversing these molecular subendotypes were identified using system pharmacology approaches. The potential effect in endometrium of selected drugs was validated in human endometrial stromal cell lines through RT-PCR, F-actin staining, and enzyme-linked immunosorbent assays. The poor-prognosis endotype ( n = 43) was associated with lower pregnancy (26.3%vs.66.0%, p = 1.99 × 10 − 5 ) and live birth (40.0%vs.87.1%, p = 0.0013), higher biochemical (30.3%vs.7.2%, p = 0.0372), and clinical miscarriage rates (42.9%vs.6.2%, p = 0.0159) when compared to good-prognosis endotype. This poor-prognosis endotype was subdivided into two molecular subendotypes, one associated with increased biochemical miscarriage rate ( n = 16; 66.7%vs.14.3%, p = 0.0022,), and the other with increased clinical miscarriage rate ( n = 27, 50%vs.0%, p = 0.0001), when compared between them, both of them characterized by abnormal decidualization features. Additionally, biochemical miscarriage subendotype highlighted also immune dysregulation as a key biological process. In silico drug prioritization identified genistein, pioglitazone, alprostadil, flunisolide, and tenoxicam as approved drugs with the potential to reverse the molecular signatures of these subendotypes. In vitro validation in endometrial stromal cells showed genistein and pioglitazone promoting decidualization, whereas alprostadil, flunisolide, and tenoxicam inhibiting well-known biomarkers of immune response, supporting their potential therapeutic role for endometrial failure. We have proposed for the first time potential drugs for an idiopathic endometrial non-timing infertility that could reduce attempts needed for achieving live birth, although further validations in patients are required towards personalised medicine. Not applicable.
No takes yet. Share an insight, caveat, or question.
Párraga-Leo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: